Target intelligence / Profile preview

Poly(ADP-ribose) polymerase family (PARP family)

Target
PARP family
Molecular classification
Enzyme, Transferase, Post-translational modifying enzyme, DNA repair enzyme
01

Overview

Poly(ADP-ribose) polymerase family proteins (PARPs) are a group of enzymes that catalyze ADP-ribosylation of target proteins using NAD+ as a substrate, with central roles in DNA repair, chromatin remodeling, and the regulation of cell death. There are at least 17 PARP family members in humans, of which PARP1, PARP2, and tankyrases are the best-characterized. PARPs respond to DNA damage by attaching long, branched chains of poly(ADP-ribose) (PAR) to themselves and other nuclear proteins, facilitating recruitment of DNA repair machinery, and modulating transcription, cell fate decisions, and genome maintenance. PARP inhibition is a clinically validated strategy for cancer therapy, especially for tumors deficient in homologous recombination repair (e.g., BRCA mutant cancers).

Other names
Poly(ADP-ribose) polymerasePARPTankyraseADP-ribosyltransferase family
02

Mechanism of action

Inhibition of ADP-ribosylation enzymatic activity\nBlockage of DNA repair pathway, leading to synthetic lethality (especially in cells with BRCA1/2 mutations)\nSensitization of tumor cells to DNA-damaging agents

03

Biological functions

DNA repair (single- and double-strand break repair)Genomic stabilityProgrammed cell death (apoptosis, necrosis)Epigenetic regulation (chromatin structure, DNA methylation)Transcriptional regulationCell divisionStress response (cellular stress, heat shock, DNA damage response)
04

Disease associations

Cancer (especially ovarian, breast, prostate, and other DNA repair-deficient cancers)Neurodegenerative diseasesInflammatory disordersOther conditions linked to DNA repair deficiency
05

Safety considerations

Hematologic toxicity (anemia, thrombocytopenia, neutropenia)Gastrointestinal effects (nausea, fatigue)Secondary malignancies (rare, especially with long-term use)Resistance via restoration of homologous recombinationOverlap with normal tissue DNA repair, risking off-target toxicity
06

Interacting drugs

Olaparib

4 more in the full profile.

07

Biomarkers

BRCA1/2 mutation status (for patient selection in cancer therapy)DNA damage response proteins (e.g., γ-H2AX)PARP1 cleavage fragments (indicator of apoptosis pathway activation)Genomic instability markers

Beyond the preview

Go deeper on Poly(ADP-ribose) polymerase family (PARP family).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poly(ADP-ribose) polymerase family (PARP family).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call